Two recent announcements—the world’s first treatment for Friedreich's ataxia (FA), whose approval was based in part on a natural history database, and a new data-sharing agreement between industry and nonprofit partners to investigate myopathy—underpin just how helpful these studies can be in establishing new collaborations to tackle rare diseases.